Apex Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Apex Biotechnology has a total shareholder equity of NT$1.8B and total debt of NT$30.0M, which brings its debt-to-equity ratio to 1.7%. Its total assets and total liabilities are NT$2.3B and NT$500.1M respectively. Apex Biotechnology's EBIT is NT$141.7M making its interest coverage ratio 119.6. It has cash and short-term investments of NT$443.9M.
Key information
1.7%
Debt to equity ratio
NT$30.00m
Debt
| Interest coverage ratio | 119.6x |
| Cash | NT$443.91m |
| Equity | NT$1.80b |
| Total liabilities | NT$500.07m |
| Total assets | NT$2.30b |
Recent financial health updates
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16
Recent updates
Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings
Mar 21Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business
Apr 17Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?
Mar 10Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?
Feb 17A Look At Apex Biotechnology's (TPE:1733) Share Price Returns
Jan 27Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture
Jan 06These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?
Nov 22Financial Position Analysis
Short Term Liabilities: 1733's short term assets (NT$1.5B) exceed its short term liabilities (NT$383.4M).
Long Term Liabilities: 1733's short term assets (NT$1.5B) exceed its long term liabilities (NT$116.7M).
Debt to Equity History and Analysis
Debt Level: 1733 has more cash than its total debt.
Reducing Debt: 1733's debt to equity ratio has reduced from 23.6% to 1.7% over the past 5 years.
Debt Coverage: 1733's debt is well covered by operating cash flow (768%).
Interest Coverage: 1733's interest payments on its debt are well covered by EBIT (119.6x coverage).